Cargando…

PICALM rs3851179 Variants Modulate Left Postcentral Cortex Thickness, CSF Amyloid β42, and Phosphorylated Tau in the Elderly

PICALM rs3851179, one of the genes most frequently linked to susceptibility of late-onset Alzheimer’s disease (LOAD), plays a crucial role in regulating amyloid precursor protein, and amyloid β (Aβ) transcytosis. To explore the effects of PICALM and AD continuum stage on cortex thickness, CSF Aβ, an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Zhiwei, Yang, Yiwen, Song, Ziyang, Ma, Mengya, Feng, Mengmeng, Liu, Yuanqing, Xing, Hanqi, Chang, Yue, Dai, Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776362/ https://www.ncbi.nlm.nih.gov/pubmed/36552141 http://dx.doi.org/10.3390/brainsci12121681

Ejemplares similares

An intronic PICALM polymorphism, rs588076, is associated with allelic expression of a PICALM isoform
por: Parikh, Ishita, et al.
Publicado: (2014)

PICALM modulates autophagy activity and tau accumulation
por: Moreau, Kevin, et al.
Publicado: (2014)

Corrigendum: PICALM modulates autophagy activity and tau accumulation
por: Moreau, Kevin, et al.
Publicado: (2015)

Abnormal CSF amyloid-β42 and tau levels in hip fracture patients without dementia
por: Oh, Esther S., et al.
Publicado: (2018)

P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status
por: Campbell, Michelle R., et al.
Publicado: (2021)

Correction: Abnormal CSF amyloid-β42 and tau levels in hip fracture patients without dementia
Publicado: (2018)

Postcentral gyrus infarction with spared proprioceptive sensation
por: Tsukui, Daisuke, et al.
Publicado: (2020)

Retinal nerve fiber layer thickness predicts CSF amyloid/tau before cognitive decline
por: Asanad, Samuel, et al.
Publicado: (2020)

Central role for PICALM in amyloid–β blood–brain barrier transcytosis and clearance
por: Zhao, Zhen, et al.
Publicado: (2015)

Standardization of Assay Procedures for Analysis of the CSF Biomarkers Amyloid β ((1-42)), Tau, and Phosphorylated Tau in Alzheimer's Disease: Report of an International Workshop
por: Teunissen, Charlotte E., et al.
Publicado: (2010)

Ventricular volume in relation to lumbar CSF levels of amyloid-β 1–42, tau and phosphorylated tau in iNPH, is there a dilution effect?
por: Lidén, Simon, et al.
Publicado: (2022)

Correction: Retinal nerve fiber layer thickness predicts CSF amyloid/tau before cognitive decline
por: Asanad, Samuel, et al.
Publicado: (2020)

Inhibition of Aβ(42) oligomerization in yeast by a PICALM ortholog and certain FDA approved drugs
por: Park, Sei-Kyoung, et al.
Publicado: (2016)

CSF sTREM2 in delirium—relation to Alzheimer’s disease CSF biomarkers Aβ42, t-tau and p-tau
por: Henjum, Kristi, et al.
Publicado: (2018)

Association of Alzheimer’s disease risk variants on the PICALM gene with PICALM expression, core biomarkers, and feature neurodegeneration
por: Xu, Wei, et al.
Publicado: (2020)

Cortical microstructural associations with CSF amyloid and pTau
por: Nir, Talia M., et al.
Publicado: (2023)

Ataxic Hemiparesis Associated with Cortical Infarct Localized in the Postcentral Gyrus
por: Kinjo, Yoshino, et al.
Publicado: (2017)

Genetics of PICALM Expression and Alzheimer's Disease
por: Parikh, Ishita, et al.
Publicado: (2014)

PICALM and Alzheimer’s Disease: An Update and Perspectives
por: Ando, Kunie, et al.
Publicado: (2022)

PICALM rescues glutamatergic neurotransmission, behavioural function and survival in a Drosophila model of Aβ42 toxicity
por: Yu, Yifan, et al.
Publicado: (2020)

A yeast model for amyloid-β aggregation exemplifies the role of membrane trafficking and PICALM in cytotoxicity
por: D’Angelo, Fabien, et al.
Publicado: (2013)

CSF protein biomarkers predicting longitudinal reduction of CSF β-amyloid42 in cognitively healthy elders
por: Mattsson, N, et al.
Publicado: (2013)

CSF tau and β-amyloid as biomarkers for mild cognitive impairment
por: Hampel, Harald, et al.
Publicado: (2004)

Detection of Alzheimer's disease amyloid beta 1‐42, p‐tau, and t‐tau assays
por: van Harten, Argonde C., et al.
Publicado: (2021)

CSF beta-amyloid 1–42 – what are we measuring in Alzheimer's disease?
por: Hu, William T, et al.
Publicado: (2015)

Diagnostic Utility of CSF Tau and Aβ (42) in Dementia: A Meta-Analysis
por: Agarwal, Rachna, et al.
Publicado: (2011)

CSF Potential Biomarkers Aβ42 and Tau: associations of Apo E Genotype
por: Kandimalla, Ramesh, et al.
Publicado: (2010)

The Interactive Effects of Age and PICALM rs541458 Polymorphism on Cognitive Performance, Brain Structure, and Function in Non-demented Elderly
por: Liu, Zhen, et al.
Publicado: (2017)

Genetic Variants of PICALM rs541458 Modulate Brain Spontaneous Activity in Older Adults With Amnestic Mild Cognitive Impairment
por: Zhuang, Liying, et al.
Publicado: (2019)

Increased CSF tau level is correlated with decreased lamina cribrosa thickness
por: Lee, Eun Ji, et al.
Publicado: (2016)

Automation vs. Experience: Measuring Alzheimer’s Beta-Amyloid 1–42 Peptide in the CSF
por: Kollhoff, Alexander L., et al.
Publicado: (2018)

Modulation of PICALM Levels Perturbs Cellular Cholesterol Homeostasis
por: Mercer, Jacob L., et al.
Publicado: (2015)

Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease
por: Parnetti, Lucilla, et al.
Publicado: (2014)

Anti-malaria drug artesunate prevents development of amyloid-β pathology in mice by upregulating PICALM at the blood-brain barrier
por: Kisler, Kassandra, et al.
Publicado: (2023)

Structural and Functional Asymmetry in Precentral and Postcentral Gyrus in Patients With Unilateral Chronic Shoulder Pain
por: Wei, Xiaoya, et al.
Publicado: (2022)

White Matter Structural Network Analysis to Differentiate Alzheimer’s Disease and Subcortical Ischemic Vascular Dementia
por: Feng, Mengmeng, et al.
Publicado: (2021)

Levels of Cortisol in CSF Are Associated With SNAP-25 and Tau Pathology but Not Amyloid-β
por: Wang, Qing, et al.
Publicado: (2018)

CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease
por: Barthélemy, Nicolas R., et al.
Publicado: (2023)

An Exploratory Study on CLU, CR1 and PICALM and Parkinson Disease
por: Gao, Jianjun, et al.
Publicado: (2011)

Correction: Anti-malaria drug artesunate prevents development of amyloid-β pathology in mice by upregulating PICALM at the blood-brain barrier
por: Kisler, Kassandra, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v3i2mkl82a3hjq5l2cv9o94i93